A virtual biotech incubator is launching with the help of Evotec and Samsara, looking for a few good scientists in need of seed cash for spinouts

By any measure, money has been pouring into the biopharma R&D field for more than 5 years now, with every stage of development crowded with investors looking for the next big thing in therapeutics.

Value inflection points are the guiding star of that multibillion-dollar business.

But a busy Samsara BioCapital, the family fund KCK and the big European CRO Evotec are backing the play of a pair of investors who have staked out a field where there doesn’t seem to be quite so much density.